- •Preface
- •Contents
- •Contributors
- •1.1 Introduction
- •1.2 Pathogenesis of AMD
- •1.2.1 Oxidative Damage
- •1.2.2 Lipofuscin Accumulation
- •1.2.4 Complement Mutations
- •1.2.5 Mitochondrial Damage
- •1.2.6 DICER 1
- •1.3 Treatment
- •1.3.1 Antioxidants
- •1.3.2 Visual Cycle Modulators
- •1.3.4 Neurotrophic Agents
- •1.3.5 Antiangiogenic Agents
- •1.3.5.1 Intracellular Angiogenic Factor Production
- •1.3.5.2 Extracellular Angiogenic Factors
- •1.3.6 Endothelial Cell Receptor Binding
- •1.3.7 Endothelial Cell Activation
- •1.3.8 Endothelial Cell Proliferation
- •1.3.9 Endothelial Cell Directional Migration
- •1.3.10 Extracellular Matrix Remodeling
- •1.3.11 Tube Formation
- •1.3.11.1 Loop Formation (Arteriovenous Differentiation)
- •1.3.11.2 Vascular Stabilization
- •1.4 Combination Therapy
- •1.5 Conclusions
- •References
- •2.1 Introduction
- •2.1.1 Complement Pathways
- •2.1.2 Oxidative Stress
- •2.3.1 The Mouse CNV Model
- •2.3.2 RPE Monolayers
- •2.3.3 Concept
- •2.5 Summary and Outlook
- •References
- •3.1 Introduction
- •3.2.1 Advanced Glycation End Products
- •3.2.2 Carboxyethylpyrrole
- •3.2.3 Oxidation Products of Lipofuscin
- •3.3 Summary and Conclusions
- •References
- •4.1 Introduction
- •4.2 Oxidative Stress and AMD
- •4.2.1 Basic Concepts on Oxidative Stress
- •4.2.2 Oxidative Stress in AMD
- •4.3 Malondialdehyde in AMD
- •4.3.1 Lipid Peroxidation and Malondialdehyde
- •4.3.2 Materials and Methods
- •4.3.2.1 RPE Cell Culture
- •4.3.2.2 Patients
- •4.3.2.3 MDA Assay
- •4.3.3 MDA Levels in Cultured RPE Cells and in Patients with AMD
- •4.4 Summary and Conclusions
- •References
- •5.1 Introduction
- •5.2 The Origin and Housing of RPE Lipofuscin
- •5.3 Bisretinoid Constituents of RPE Lipofuscin
- •5.3.1 A2E, Isomers and Precursors
- •5.3.4 Photooxidized Forms of Bisretinoid Pigments
- •5.4 Photoreactivity of RPE Lipofuscin
- •5.5 Photooxidation of RPE Bisretinoids
- •5.6 Bisretinoid Photodegradation
- •5.7 Potential for Cell and Tissue Damage
- •5.9 A Role for Antioxidants
- •5.10 Conclusions
- •References
- •6.1 Introduction
- •6.1.1 RPE Lipofuscin Accumulation with Age and Relation to AMD
- •6.1.2 Known Chromophores Found in RPE Lipofuscin and the Mechanism of Damage
- •6.1.3 Formation of Higher Molecular Weight Material
- •6.1.4 Current Studies and Possible Structures of Higher Molecular Weight Products
- •6.1.4.1 Lipofuscin Extracts
- •6.1.4.3 Esters and Aldehydes
- •6.2 Conclusions
- •References
- •7.2 DHA in Photoreceptor Cells
- •7.3 Neuroprotectin D1 Synthesis is an Early Response to Oxidative Stress in RPE Cells
- •7.5 Neurotrophins Trigger the Synthesis and Polarized Secretion of Neuroprotectin D1 from Human RPE Cells
- •7.6 Photoreceptor Outer Segment Phagocytosis Induces RPE Cell Survival Signaling with Associated Synthesis of NPD1 During Oxidative Stress
- •References
- •8.1 Introduction
- •8.2.1 Subcellular Localization
- •8.2.2 Expression Levels in the Retina
- •8.4.3 Regulation of RDH12 Expression and Activity During Chronic and Acute Stress
- •8.5 RDH12 and Leber Congenital Amaurosis
- •8.5.1 Inactivating Mutations of RDH12
- •8.5.2 Loss of Which RDH12 Function Induces LCA?
- •8.6 Summary and Conclusions
- •References
- •9.1 Introduction
- •9.2 GSH Metabolism: General Principles
- •9.2.2 Role of Mitochondrial GSH in Protection
- •9.2.3 GSH as a ROS Scavenger
- •9.2.4 GSH Distribution in the Retina and RPE in Health and Disease
- •9.5 Future Perspectives
- •References
- •10.1 Introduction
- •10.2 Mitochondria
- •10.2.1 Mitochondrial Biogenesis and Maintenance
- •10.2.2 Mitochondrial Removal and Degradation
- •10.3 Mitochondria and Reactive Oxygen Species
- •10.3.1 Reactive Oxygen and Nitrogen Species (ROS and RNS)
- •10.3.2 Mitochondria are a Major Source of Intracellular ROS
- •10.3.3 Other Sources of ROS in the Retina
- •10.4 The Mitochondrial Genome
- •10.4.1 Susceptibility of Mitochondrial DNA to Oxidative Stress
- •10.4.2 Mitochondrial DNA Damage
- •10.4.3 Mitochondrial DNA Repair Pathways
- •10.4.4 The Mitochondrial Base Excision Repair (mtBER) Pathway
- •10.4.6 Other Mitochondrial DNA Repair Pathways
- •10.4.6.2 Mismatch Repair (MMR)
- •10.4.6.3 Translesion Synthesis (TLS) and Damage Tolerance
- •10.4.6.4 Nucleotide Excision Repair (NER)
- •10.4.7 Intramitochondrial Localization of DNA Repair Proteins
- •10.4.8 mtDNA Damage Sensing and Signaling
- •10.4.9 Import of Nuclear Encoded DNA Repair Enzymes into the Mitochondria
- •10.5 Mitochondrial DNA Damage/Repair in the Retina and RPE
- •10.5.1 Mitochondrial DNA Damage/Repair in the RPE
- •10.5.2 DNA Repair and the Adaptive Response in the RPE
- •10.6 Pathologies Associated with Mitochondrial Dysfunction and Oxidative Stress in the Retina
- •10.6.2 Diabetic Retinopathy
- •10.6.3 Glaucoma
- •10.6.4 Uveitis
- •10.7 Pathologies Associated with Inherited Mitochondrial Disorders
- •10.8 Potential Therapeutic Options for Targeting Mitochondrial DNA Damage
- •10.8.1 Mitochondrial Biogenesis
- •10.8.2 Enhancing mtDNA Repair
- •10.8.3 Antioxidants
- •10.8.4 Autophagy
- •10.9 Conclusion
- •References
- •11.1 Introduction
- •11.2 ER Function in Normal Physiology
- •11.2.1 Major Roles of Rough ER (RER) and Smooth ER (SER)
- •11.2.2 ER and Oxidative Protein Folding
- •11.2.3 ER Resident Proteins
- •11.2.4 Potential Threat to ER Function in RPE
- •11.3 ER Response to Oxidative Stress in RPE
- •11.3.2 Initiation of UPR to Alleviate ER Burden
- •11.4 Chronic ER Stress and Oxidative Stress in the Vicious Cycle of Apoptosis Induction
- •11.5 Future Perspectives
- •References
- •12.1 Introduction
- •12.2 Iron Homeostasis
- •12.2.1 General Iron Homeostasis
- •12.2.2 Iron Import into the Retina
- •12.2.2.1 Transferrin Mediated Transport
- •12.2.2.3 Dexras
- •12.2.3 Iron Storage
- •12.2.3.1 Ferritin
- •12.2.3.2 Mitochondrial Ferritin
- •12.2.4 Iron Export
- •12.2.4.1 Ceruloplasmin
- •12.2.4.2 Hephaestin
- •12.2.4.3 Ferroportin and Hepcidin
- •12.3 Disruption of Iron Homeostasis and Oxidative Damage
- •12.4 Retinal Disorders Resulting from Abnormal Retinal Iron Metabolism
- •12.4.2 Aceruloplasminemia
- •12.4.3 Hemochromatosis
- •12.4.4 Friedreich’s Ataxia
- •12.4.6 Siderosis
- •12.4.7 Subretinal Hemorrhage
- •12.5 Potential Therapeutics
- •References
- •13.1 Vascular Endothelial Growth Factor and Its Functions in the Retina
- •13.1.1 VEGF Isoforms
- •13.1.2 VEGF Functions
- •13.1.3 Cells Secreting VEGF in the Retina
- •13.1.3.1 Retinal Pigment Epithelium
- •13.1.3.2 Müller Cells
- •13.1.3.3 Astrocytes
- •13.1.3.4 Pericytes
- •13.1.4 VEGF Receptors and VEGF Induced Signal Transduction
- •13.1.4.1 VEGF Receptors
- •VEGFR-1
- •VEGFR-2
- •Neuropilin
- •Heparan Sulfate Proteoglycan
- •13.2 Regulation of VEGF Expression
- •13.2.1 Transcriptional Regulation
- •13.2.2 Translational Regulation
- •13.2.3 Hypoxia Induced VEGF Regulation
- •13.2.4 Posttranslational Regulation
- •13.2.5 Autocrine VEGF Regulation
- •13.2.6 Pathological VEGF Production
- •13.2.6.1 Hyperglycemia
- •13.2.6.2 Oxidative Stress
- •13.2.6.3 Cytokines
- •13.2.6.4 Endoplasmic Reticulum
- •13.2.6.5 Additional Factors
- •13.3.1 Pegaptanib
- •13.3.2 Bevacizumab and Ranibizumab
- •13.3.4 siRNA
- •13.3.5 Small Molecule Tryrosine Kinase Inhibitors
- •13.3.6 Other Inhibitors
- •13.4.2 Interaction of VEGF Antagonists with Antiangiogenic VEGFxxxb
- •13.5 Conclusion
- •References
- •14.1 Introduction
- •14.2 NADPH Oxidase and Redox Signaling
- •14.3 Expression of NADPH Oxidase Subunit p22phox in the Retina
- •14.4 NADPH Oxidase and Choroidal Neovascularization
- •14.5 Implication and Therapeutic Potential of NADPH Oxidase in Development of CNV
- •14.6 Summary and Future Perspective
- •References
- •15.1 Introduction
- •15.2 Aging
- •15.3 Deposition and Formation of Oxidized LDL
- •15.6 Treatments for AMD
- •15.7 Conclusions
- •References
- •16.1 Introduction
- •16.2 HGF and Its Receptor (MET)
- •16.2.1 Production and Secretion of HGF
- •16.2.2 MET and Biological Effects of HGF
- •16.2.3 Signaling Pathways of HGF
- •16.2.4 HGF and MET in Disease States
- •16.4 HGF Protects RPE Cells from Oxidative Stress
- •16.4.1 HGF and RPE Cells
- •16.4.2 HGF Promotes Cell Survival
- •16.4.3 HGF Protects Cells from Oxidative Stress
- •16.4.4 HGF Protects RPE Cells from Hydrogen Peroxide
- •16.4.5 HGF Protects RPE Cells Against Ceramide Damage
- •16.4.6 HGF Protects RPE Cells from Glutathione Depletion
- •References
- •17.1 Introduction
- •17.2.1 Fundoscopy
- •17.2.2 Histology
- •17.2.3 Ultrastructure
- •17.3.1 Lipofuscin (A2E)
- •17.3.3 HtrA2/Omi
- •References
- •18.1 Introduction
- •18.2 Systemic Markers of Oxidative Stress
- •18.2.1 Redox Status
- •18.2.2 DNA Damage
- •18.2.4 Lipid Peroxidation
- •18.3 Defenses Against Oxidative Stress
- •18.3.1 Antioxidants
- •18.3.2 Antioxidant Enzymes
- •18.4 Oxidative Stress and Genetics
- •18.4.1 Antioxidant Enzyme Polymorphisms
- •18.5 Environmental Exposures and Oxidative Stress
- •18.5.1 Smoking
- •18.5.2 Light Exposure
- •18.6 AMD Treatments and Oxidative Stress
- •18.8 Summary and Conclusions
- •References
- •19.1 Characteristics of Cerium Oxide Nanoparticles
- •19.3 Mechanism of Nanoceria Uptake, Internalization, and Localization in the Cell
- •19.4 Biological Effect, Functional Mechanism, and Applications
- •19.4.1 Bacteria
- •19.4.2 Plants
- •19.4.3 Medical Usage
- •19.4.3.1 Radioprotectants
- •19.4.3.2 Burn Treatment
- •19.4.4 Medical Imaging
- •19.5 Stability of Nanoceria Under storage Conditions and Its Longevity in the Cell In Vivo
- •19.6 Oxidative Damage Results in Neurodegeneration
- •19.7.1 Prolong Cellular Life Span
- •19.7.2 Cardioprotection
- •19.8 Treatment of Ocular Disorders
- •19.8.1 Methodology
- •19.8.2 Prevention of Light Damage and Rescue of Retinal Function
- •19.8.3 Treatment of Degenerative Ocular Diseases
- •19.8.4 Treatment of Ocular Neovascular Diseases
- •19.9 Toxicity and Environmental Impacts
- •19.10 Conclusion and Future Directions
- •References
- •20.1 Introduction
- •20.2 Retinal Progenitor Cells (RPCs) Are Multipotential
- •20.4 Therapeutic Strategies for Repair and Regeneration of Retinal Cells: Repair of the RPE
- •20.5 Challenges for RPE Stem Cell Therapy
- •20.6 Characterization of RPE-Like Cells Derived from BMDCs
- •20.7 BMDCs Differentiate into Retinal Cells
- •20.8 Summary and Future of Cell Therapy for Dysfunctional RPE
- •References
- •21.1 Introduction
- •21.2 Carotenoids in Retinal Diseases
- •21.4 Polyphenols or Phenolic Esters in Retinopathies
- •21.4.1 Caffeic Acid Phenethyl Ester
- •21.4.2 Catechin
- •21.4.3 Curcumin
- •21.4.4 Proanthocyanidin
- •21.4.5 Resveratrol
- •21.5.2 Sulforaphane
- •21.6 Vitamins in Retinopathies
- •21.6.1 Vitamin A
- •21.7 Perspectives
- •References
- •22.1 Introduction
- •22.1.1 Neuroprotection as a Strategy for Retinal Degenerative Disease
- •22.2.2 Putative Mechanisms of CNS Neuroprotection
- •22.3.9 Conclusion
- •22.4 Mechanisms of Retinal Protection
- •22.4.1 Insights from In Vitro Models
- •22.5.1 Background to the Disease and the Associated Preclinical Data
- •22.5.2 Overview of the Clinical Development Program
- •References
- •23.1 Introduction
- •23.2 Pathogenesis
- •23.4 Pegaptanib
- •23.5 Bevacizumab
- •23.6 Ranibizumab
- •23.7.1 Ranibizumab
- •23.7.2 Bevacizumab
- •23.8 Comparison of AMD Treatment Trials (CATT)
- •23.9 Management of Nonresponders
- •23.11 Conclusion
- •References
- •24.1 Introduction
- •24.2 Rationale for Combination Therapy
- •24.3 Supporting Evidence for Combination Therapy
- •24.4 Currently Applied Combination Therapies
- •24.5 Challenges for Combination Therapy
- •References
- •25.1 Human Endothelial Progenitor Cells
- •25.3 Function of EPCs
- •25.3.1 EPCs in Vascular Repair and Neovascularization
- •25.4 EPCs in Diabetes
- •25.4.1 EPC as a Biomarker in Diabetes
- •25.4.1.1 EPC Dysfunction in Diabetes
- •25.4.1.2 Oxidative Stress and EPC Dysfunction in Diabetes
- •25.4.1.3 Therapeutic Angiogenesis by EPCs in Diabetic Retinopathy
- •25.5 Conclusion
- •References
- •26.1 Introduction
- •26.1.1 Nitric Oxide
- •26.1.2 Nitric Oxide Regulation
- •26.1.3 Nitric Oxide in Normal and Pathophysiological Conditions
- •26.2 Retinal Vascular Diseases: The Role of iNOS
- •26.2.1 Nitric Oxide in Diabetic Retinopathy
- •26.2.2 iNOS in Diabetic Retinopathy
- •26.2.2.2 iNOS and Leukocyte Adhesion to Retinal Vessels
- •26.2.2.3 iNOS and Retinal Cell Death
- •26.2.3 Proliferative Retinal Diseases
- •26.2.3.1 iNOS and Proliferative Retinal Diseases
- •26.2.3.2 iNOS and Ocular Neovascularization in Retinal Vascular Diseases
- •26.3 Conclusions
- •References
- •27.1 Introduction
- •27.2 Animal Model
- •27.2.1 LHP Preparation and Injection Procedure
- •27.2.2 Acridine Orange Digital Fluorography
- •27.3 Experimental Results
- •27.3.1 Leukocyte Rolling
- •27.3.2 Accumulated Leukocytes in the Retinal Microcirculation
- •27.3.3 Diameter of Major Retinal Vessels
- •27.3.4 SOD Treatment
- •27.4 Discussion
- •27.5 Conclusions
- •References
- •28.1 Introduction
- •28.1.2 Metabolism and Balance in Generation and Quenching of ROS
- •28.2 Role of Oxygen Concentration on Generation of ROS in the Developing Retina
- •28.3.1 Perinatal Considerations
- •28.3.2 Neonatal Considerations
- •28.3.2.1 Polyunsaturated Fatty Acids in Retina and Brain
- •28.3.2.2 Increased Oxidation
- •28.3.2.3 Reduced Antioxidant Enzyme Systems
- •28.3.3 Environmental Stimuli
- •28.3.3.1 Light
- •28.3.3.2 Oxygen Changes in Development and Prematurity
- •28.3.3.3 Nutrition
- •28.3.3.4 Effect of Blood Transfusions on Oxidative Stress in Prematurity
- •28.4 Evidence from Animal Models
- •28.4.1 Background
- •28.4.2 Effects of Hypoxia on Bioenergetic Oxygen Sensor Mechanisms and Related to ROP
- •28.4.2.2 NADPH Oxidase
- •28.4.2.3 Cytochrome p450 Monooxygenases (CYP)
- •28.4.2.4 eNOS
- •28.4.2.5 Heme Oxygenase
- •28.4.2.6 Metabolic Effects of Hypoxia
- •28.4.3 Laboratory Evidence of Antioxidants on Animal Models of ROP
- •28.5 Clinical Studies of Antioxidants on ROP
- •28.6 Genetics
- •28.7 Summary
- •References
- •29.1 Introduction
- •29.1.1 Oxidative Stress in Glaucoma
- •29.1.2 Oxidative Stress in Diabetic Retinopathy
- •29.1.3 Oxidative Stress in Age Related Macular Degeneration
- •29.1.4 Vascular Endothelial Growth Factor
- •29.1.5 VEGF Mediated Neuroprotection
- •29.1.6 Mechanisms of VEGF Protection Against Oxidative Stress
- •References
- •30.1 Introduction
- •30.1.1 Oxidation and Oxidative Stress
- •30.1.2 Reactive Oxygen Intermediates
- •30.1.3 ROIs and Cellular Retinal Damage
- •30.1.4 Light, Cellular Retinal Damage and AMD
- •30.1.5 Carotenoids
- •30.1.6 Chemistry of Carotenoids: Basic Structural Components
- •30.2 Building Blocks
- •30.3 The Polyene Backbone
- •30.5 Terminal Groups
- •30.5.1 Source of Macular Carotenoids
- •30.5.2 Macular Carotenoids: The Origins of Macular Pigment
- •30.5.3 The Functions of the Macular Carotenoids as Macular Pigment for AMD
- •30.6 Antioxidant Properties
- •30.6.1 The Functions of the Macular Carotenoids as Macular Pigment for Visual Performance
- •References
- •31.1 Introduction
- •31.2 Composition and Distribution
- •31.3 Selective Uptake and Deposition Process of MP
- •31.4 Measurements
- •31.4.1 Heterochromatic Flicker Photometry
- •31.4.4 Resonance Raman Spectroscopy
- •31.5 Antioxidant Mechanism of MP and Its Relation to Retinal Health and Disease
- •31.5.1 Oxidative Stress in Human Retina and the Antioxidant Mechanism of MP
- •31.5.2 MP in Human Eye Health and Disease
- •31.5.2.2 MacTel
- •31.5.2.3 Acuity
- •31.6 Ocular Carotenoid Supplementation Studies
- •31.7 Conclusion
- •References
- •Index
- •About the Authors
166 |
A. Saadi et al. |
RDH |
Retinol dehydrogenase |
ROS |
Reactive oxygen species |
RPE |
Retinal pigment epithelium |
SDR |
Short-chain dehydrogenase/reductase |
8.1Introduction
Rod and cone photoreceptor cells are photosensitive; they detect the presence of photons through the 11-cis retinal chromophore bound to opsin proteins. Light isomerizes 11-cis retinal to all-trans retinal, which then dissociates from opsin. This photoisomerization is the initial event that triggers the visual transduction pathway, activation of second order neurons, and eventually transmission of the signal to the brain. Under constant illumination, 11-cis retinal needs to be replaced and all-trans retinal needs to be removed from the vicinity of opsin so that photoreceptor cells continue to have optimum sensitivity to light. Retinol dehydrogenases (RDHs) located in photoreceptor outer segments and in retinal pigment epithelium (RPE) cells participate in these very important functions [1]. Surprisingly, several RDHs expressed in photoreceptor cells are not located in the outer segment but in the inner segment only. Inner segment RDHs are RDH11 [2, 3], RDH12 [4Ð6], and RDH13 [7]. Their physiological role(s) are not completely understood. We propose the hypothesis that inner segment RDHs play a role in the detoxiÞcation of polyunsaturated fatty acids (PUFAs) oxidation products. These toxic products are easily generated in photoreceptor cells and have to be reduced to keep the cells alive and functional.
8.2Subcellular Localization, Expression Levels in the Retina, and Substrate Specificity
8.2.1Subcellular Localization
To determine the physiological role of an enzyme in vivo, it is important to determine its localization, relative to that of its possible substrates. RDH11, 12, and 13 are located in the inner segments of rod and cone photoreceptors. RDH11 and 12 are integral membrane proteins and thus cannot be extracted from membrane fractions by alkaline treatment [2]. Both enzymes are inserted in the membrane through a stretch of ~20 amino-terminal hydrophobic residues [2, 7]. RDH13 does not contain this stretch of hydrophobic residues and is a peripheral membrane protein, as demonstrated by the fact that it can be extracted from membrane fractions by alkaline treatment [8]. In previous studies, we showed that RDH11 is localized in the Golgi apparatus in spermatocytes [2] and in various cultured cells (unpublished observation). Here, we performed a subcellular fractionation of retinal tissues through ultracentrifugation on sucrose gradient [9]. As shown in Fig. 8.1, RDH12
8 Role of Photoreceptor Retinol Dehydrogenases in DetoxiÞcationÉ |
167 |
Fig. 8.1 Subcellular fractionation of mouse retina. Mouse retinas were pooled, homogenized, and subjected to ultracentrifugation as described [9] to prepare the total membrane pellet (Mb) and the cytosolic (C) fractions. Mb fraction was resuspended, protein concentration was measured, and 10 mg of each fraction was subjected to SDS-PAGE. The Mb fraction was further fractionated by ultracentrifugation on sucrose step gradients of 1.25, 1.1, and 0.25 M sucrose solutions as described [9]. The Golgi-enriched fraction was collected at the interphase of the 0.25 and 1.1 M sucrose solutions; the ER-enriched fraction was collected at the interphase of the 1.1 and 1.25 M sucrose solutions; and the microsome pellet (M) was at the bottom of the tube. Protein concentration was measured and 5 mg of each fraction was subjected to SDS-PAGE. Immunoblotting was performed as described [10] with anti-RDH11 and anti-RDH12 polyclonal antibodies
is found in Golgiand endoplasmic reticulum (ER)-enriched fractions and RDH11 is detected only in the Golgi-enriched fractions. Another study showed that RDH13 is a mitochondrial enzyme, localized within the intermembrane space, and associated with the inner mitochondrial membrane [8]. These distinct subcellular localizations suggest a speciÞc role for RDH13 in the mitochondria, RDH12 in the ER, and redundant functions for RDH11 and RDH12 in the Golgi.
8.2.2Expression Levels in the Retina
To determine the relative expression levels of these enzymes in the retina, we compared mRNA levels by quantitative RT-PCR. As shown in Fig. 8.2, the level of Rdh12 mRNA in BALB/c mouse retina is ~7-fold higher than the level of Rdh11 and ~200-fold higher than the level of Rdh13. In a previous study [10], using a different strain of mice, we found that the level of Rdh12 mRNA in C57BL6 was ~40fold higher than the level of Rdh11. We also compared expression levels of RDH11 and RDH12 proteins and, after calibration of our speciÞc antibodies, found that
168 |
A. Saadi et al. |
Fig. 8.2 Quantitative expression of Rdhs in the mouse retina. Total RNAs were prepared from retinas of adult BALB/c mice raised under dim cyclic light and subjected to quantitative RT-PCR as described [10]. Each value represents the average amount of indicated mRNA, relative to the value of the housekeeping gene Rpl19, arbitrarily deÞned as 1. Error bars represent the standard error for the four samples
RDH12 was ~7-fold higher than RDH11 in C57BL6 mouse retina [10]. Taken together, these experiments show that, of these three enzymes, RDH12 is the most abundantly expressed RDH in photoreceptor inner segments.
8.2.3Substrate Specificity
RDH11, 12, and 13 are oxidoreductase enzymes that belong to the short-chain dehydrogenase/reductase (SDR) family [2, 7]. Their substrate and coenzyme speciÞcities have been evaluated in vitro. Similarly to RDHs located in photoreceptor outer segments, all three RDHs were found to reduce all-trans retinal and other retinaldehydes (in the cis conÞguration) to corresponding retinols, using NADPH as cofactor [7, 8]. An additional group of substrates was found for RDH11 [2] and RDH12 [11]. Various aldehyde-containing molecules, formed by a chain of 8Ð10 carbons and containing 0Ð2 unsaturated carbon bonds, 0 or 1 hydroxyl group and 1 aldehyde group were found to be reduced by RDH11 and RDH12 to the corresponding alcohols [2, 11]. These aldehydes are produced in cells by the oxidation of membrane PUFAs [12]. PUFAs are easily oxidized when attacked by reactive oxygen species (ROS) formed within the mitochondria as byproducts of the electron transport chain [13]. Each PUFA produces speciÞc oxidation products. For example, 4-hydroxynonenal (4-HNE; 9 carbons, 1 unsaturation, 1 hydroxyl group, and 1 aldehyde group) is an oxidation product of w-6 arachidonic and linoleic fatty acids [14]. 4-HNE is the most abundant and toxic end product of lipid oxidation found in tissues [15, 16]. In vitro studies showed that RDH11 and RDH12 can reduce 4-HNE [2, 11]. The enzymatic activity of RDH13 has not been directly tested with 4-HNE or other lipid oxidation products.
Indirect testing of the substrate speciÞcity for various aldehyde-containing molecules was performed by competition experiments. In these experiments, the
8 Role of Photoreceptor Retinol Dehydrogenases in DetoxiÞcationÉ |
169 |
RDH of interest is incubated with a limiting concentration of all-trans retinal as the known substrate. The potential substrate being tested is added to the reaction in increasing concentrations. If a potential substrate competes with all-trans retinal (by binding to the same site), it is then considered to be a true substrate of the enzyme. When we and others performed this type of experiment with RDH12 (unpublished) and RDH13 [8], none of the aldehydes tested including 4-HNE were able to compete with all-trans retinal, even at high concentrations. This is surprising because the direct activity of RDH12 on 4-HNE has been demonstrated [11]. Absence of competition in this case could suggest that RDH12 has double substrate speciÞcity, involving two distinct substrate-binding sites. No conclusion can be drawn for RDH13 before its activity is directly tested with 4-HNE as substrate.
8.3Detoxification of 4-HNE in Cultured Cells
Shortand medium-chain aldehydes produced by oxidation of lipids have been shown to mediate oxidative damage in various pathological situations, especially in neurodegenerative diseases [17]. Because 4-HNE is the most abundant and most toxic end product of lipid oxidation and was found to be a substrate for RDH11 and RDH12 in vitro, it was important to determine if these enzymes were able to protect cells against the toxicity of 4-HNE. In a series of experiments, we generated stable cell lines, expressing RDH11, RDH12 (wild type or inactive mutant), or RDH13 and compared their sensitivities to 4-HNE-induced apoptosis. This assay allowed us to indirectly test the activity of RDH13 with 4-HNE in a way that did not involve competition with all-trans retinal. Apoptosis was quantiÞed with ßow cytometry using annexin-V staining.
In a Þrst study [18], we showed that with 75 mM of 4-HNE in the culture medium, nearly 100% of cells expressing either RDH11 or RDH12 were protected, while about 40% of control nonexpressing cells were annexin-V positive. This signiÞcant protection demonstrates that RDH11 and RDH12 are able to efÞciently detoxify 4-HNE in cells, most likely through their ability to reduce it to a nontoxic alcohol. Our data also showed that this protection could be overwhelmed with increasing concentrations of 4-HNE [18].
We then investigated whether the enzymatic activity of RDH12 was necessary for protection against 4-HNE-induced apoptosis using stable cell lines expressing active or inactive variants of this protein [18]. In studies of human RDH12, wild-type R161 and the common variant R161Q have been previously reported to exhibit similar all- trans RDH activities [19, 20]. On the other hand, the T49M mutant showed a dramatic reduction in the ability to produce all-trans retinol from all-trans retinal, explained by a defect in cofactor binding [19]. As expected, both the wild-type and common variant of human RDH12 signiÞcantly protected 40Ð50% of cells against 4-HNE-induced apoptosis. On the other hand, the inactive T49M mutant did not protect the cells. This is not due to a lower expression level of the mutant because all three variants were expressed similarly in our stable cell lines [18]. This experiment demonstrated that the enzymatic activity of RDH12 is essential to detoxify 4-HNE in cells.
170 |
A. Saadi et al. |
Fig. 8.3 DetoxiÞcation of 4-HNE by RDHs in cultured cells. The cells were transfected with the expression plasmid pcDNA3.1/HIS, expressing human RDH12 variants R161 (wild-type), T49M (mutant inducing LCA), and mouse RDH13. Stable cell lines were established and maintained by growing the cells in complete DMEM medium containing G418 (1 mg/mL). The cells were treated overnight (20 h) with 60 mM of 4-HNE in complete DMEM. The cells were harvested the next day for ßow cytometry analysis as described [18]. Percent cell death in each stable cell line was then expressed in comparison to cell death in the inactive mutant RDH12 T49M-expressing cells, set at 100%. Error bars represent the standard deviation for three experiments
Finally, we generated stable cell lines, one expressing wild-type RDH12 (R161), one expressing the inactive RDH12 mutant T49M, and one expressing RDH13. As shown in Fig. 8.3, the presence of recombinant RDH12 wild-type and RDH13 protects about 50% of the cells from apoptosis induced by 60 mM 4-HNE. On the other hand, the inactive, T49M mutant did not protect the cells. This result strongly suggests that RDH13 can reduce 4-HNE. However, this will have to be conÞrmed by direct enzymatic assay with the substrate. Taken together, these experiments show that all three RDHs can detoxify 4-HNE in cultured cells. These experiments were performed in presence of high levels of enzyme and substrate. They suggest the possibility that such reaction could take place in photoreceptor inner segments; however, they do not demonstrate it.
8.4Detoxification of 4-HNE in the Retina
8.4.1Colocalization of 4-HNE and RDHs in Photoreceptor Inner Segments
For RDH mediated reduction to take place in vivo, there should be colocalization of enzyme and substrate. The localization of 4-HNE was investigated in rat [21] and
8 Role of Photoreceptor Retinol Dehydrogenases in DetoxiÞcationÉ |
171 |
mouse retinas [18], after exposure to bright light. Exposure to bright light causes photoreceptor apoptosis, which can be blocked by various types of antioxidants demonstrating that oxidative damage mediates light-induced photoreceptor cell death [22Ð25]. ROS can directly attack PUFAs and initiate an autoampliÞed chain reaction of lipid oxidation in cellular membranes. This causes a nonenzymatic PUFA degradation into a variety of oxidized products, including shortand mediumchain reactive aldehydes such as 4-HNE [14]. 4-HNE can then react readily with histidine, cysteine, or lysine residues of proteins forming MichaelÕs adducts [26]. This reaction leads to a variety of effects such as inhibition of enzyme activity; targeting of modiÞed proteins for degradation; inhibition of protein, RNA, and DNA synthesis; cell cycle arrest; and apoptosis [12, 14, 15, 27]. Reactive aldehydes exert cytotoxicity largely because of their facile reactivity with proteins. A study by Tanito et al. [21] assessed the formation of 4-HNE-modiÞed proteins in lightexposed rat retinas by using speciÞc antibodies against 4-HNE-protein Michael adducts. This study showed that exposure to intense light increases 4-HNE protein modiÞcation in the retina and that this effect is reversed by prior injection of the antioxidant phenyl-N-tert-butylnitrone (PBN). The study also showed that protein modiÞcations by 4-HNE are early events that precede apoptosis and subsequent photoreceptor cell death. A more detailed analysis has been performed by immunohistochemistry and cell fractionation to investigate the localization of protein modiÞcations by 4-HNE [21]. 4-HNE-protein adducts accumulated signiÞcantly in rod inner segments and photoreceptor nuclei [21]. We have recently investigated the localization of light-induced 4-HNE adducts in BALB/c mouse retina [18]. We found that light-dependent accumulation of adduct occurs in the RPE, the photoreceptor cells, and the interneurons. In photoreceptor cells, adducts accumulate in the inner segments, cell bodies, and synaptic termini, but not in the outer segments [18]. The overlapping localization of RDH11, 12, and 13 with 4-HNE in photoreceptor inner segments suggests that 4-HNE could be a physiological substrate of these enzymes in the retina.
8.4.2Retinal Levels of 4-HNE in Rdh11 and Rdh12 Knockout Mice
Since 4-HNE colocalizes with RDHs in photoreceptor inner segments, we investigated whether these enzymes could detoxify endogenous 4-HNE, by measuring retinal levels of 4-HNE-protein adducts in existing mouse lines with disrupted Rdh11 or Rdh12 genes [18]. We Þrst quantiÞed 4-HNE-protein adduct in retinal homogenates of albino BALB/c wild-type, Rdh11 and Rdh12 knockout mice raised under dim cyclic light. The level of 4-HNE-modiÞed proteins was signiÞcantly higher (60% increase) in the Rdh12 knockout retina when compared to the wild-type retina [18]. As shown in Fig. 8.4, this difference between wild-type and knockout was further increased when we compared microsomal fractions (enriched in RDH12) instead of comparing retinal homogenates (60% increase in retinal
172 |
A. Saadi et al. |
Fig. 8.4 QuantiÞcation of 4-HNE-protein adduct in mouse retina. BALB/c wild-type and Rdh12 knockout mice were raised in dim cyclic light for 8Ð12 weeks. Microsomal fractions were prepared as described [18], and equal aliquots
(10 mg) of retinal microsomes were analyzed by dot blot as described [18]. Six mice were used in each group and the mean and standard error are plotted. Results were compared using the StudentÕs t test for signiÞcance.
* = p < 0.05; ** = p < 0.001; and *** = p < 0.0001
homogenates vs. 80% increase in retinal microsomes). By contrast, in the Rdh11 knockout retina, the basal level of adducts is similar to that of the wild-type [18]. This result might simply reßect the fact that the expression level of RDH11 is much lower than that of RDH12, making the relative contribution of RDH11 to the detoxiÞcation of 4-HNE negligible in presence of RDH12. In the future, experiments comparing the level of adduct in retinas of Rdh12 knockout and Rdh11/Rdh12 double knockout mice might uncover a redundant detoxiÞcation role for RDH11.
Surprisingly, after exposure to bright light, adduct accumulation reached a maximum level that was similar in all three mouse lines [18]. This result suggests that neither RDH11 nor RDH12 are involved in detoxiÞcation during acute stress. It is possible that their enzymatic activities are overwhelmed at this level of stress. Taken together, these results suggest that RDH12 has a housekeeping detoxiÞcation role in photoreceptor cells, reducing 4-HNE produced by a basal level of lipid oxidation taking place constantly in mouse retina. In this case, RDH12 would exert its physiological function primarily in the dark or in moderate lighting, keeping 4-HNE at low levels. Because Rdh13 knockout mice are not available, the relative contribution of RDH13 to 4-HNE detoxiÞcation in the retina could not be tested. The physiological role of RDH13 could be to reduce reactive aldehydes produced by oxidation of PUFAs within mitochondrial inner membrane, following local production of ROS. This function could be very important to stop the propagation of oxidative damage outside the mitochondria into other compartments of the cell. To further determine the relative contributions and redundancy of these RDHs for detoxiÞcation of 4-HNE and other lipid oxidation products, various combinations of double knockouts and the triple knockout mouse lines will be needed.
